Clinical trials: Thrombocytopathy
Immune Thrombocytopenia, ITP
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
This is a multi-center, observational, Phase 4 study in patients with Immune Thrombocytopenia (ITP) designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge…
- Trial name
- ADOPT (NCT04943042)
- Testing
- Avatrombopag
- Where
- 55 sites in Croatia, Czechia and 7 more
- Volunteers
- 199 people
- Sponsor
- Swedish Orphan Biovitrum
Von Willebrand Disease, Blood Coagulation Disorders
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.
- Conditions
- Von Willebrand Disease, Blood Coagulation Disorders, Blood Platelet Disorders, Hematologic Disease
- Trial name
- NCT00168090
- Testing
- Blood coagulation Factor VIII and vWF, human
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- CSL Behring
Myeloproliferative Neoplasm, Unclassifiable, Essential Thrombocythemia
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
A phase-I-first in man study in patients with calreticulin(CALR)-mutant MPN by vaccinating with exon 9 mutated peptide with the adjuvant Montanide ISA-51 to monitor safety and toxicity and the immunological response to…
- Conditions
- Myeloproliferative Neoplasm, Unclassifiable, Essential Thrombocythemia, Myelofibrosis
- Trial name
- NCT03566446
- Testing
- CALRLong36 peptide
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Inge Marie Svane
Recurrent Colorectal Carcinoma, Thrombopenia
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with…
- Trial name
- NCT03823079
- Testing
- rhTPO, irinotecan, Raltitrexed
- Volunteers
- 50 people
- Sponsor
- Fudan University
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF)…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera
- Trial name
- NCT02124746
- Testing
- Momelotinib
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 87 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Immune Thrombocytopenia
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
Hydroxychloroquine has been reported to have a clinically significant effect on the platelet count in systemic lupus thrombocytopenia. Its action may be due to its immune modulator effect.
- Trial name
- NCT03229746
- Testing
- Hydroxychloroquine, vincristine, azathioprine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Primary Immune Thrombocytopenia (ITP)
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to <18 years of age)…
- Trial name
- VAYHIT-P (NCT07660172)
- Testing
- Ianalumab, Eltrombopag
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Thrombocytopenia
Effects of a Platelet Transfusion Best Practices Alert
This study is to determine the effectiveness of a computerized clinical decision support tool (Best Practice Alert - BPA) in reducing unnecessary platelet transfusions based on guidelines published by national transfusion…
- Trial name
- NCT04155775
- Testing
- Computer electronic health record alert (Best Practice Alert - BPA)
- Where
- United States
- Volunteers
- 446 people
- Sponsor
- Stanford University
Corona Virus Infection
Cytopenias in Hospitalized Patients of Corona Virus Infection(COVID-19) During First and Other Waves
Demographic, Clinical and laboratory data as well as outcome of total 202 COVID-19 patients who were Polymerase Chain Reaction (PCR) positive and admitted in Fatima memorial Hospital, Lahore, Pakistan, was collected during first…
- Trial name
- NCT05258812
- Where
- Pakistan
- Volunteers
- 202 people
- Sponsor
- Fatima Memorial Hospital
Thrombocytopaenia
Meta-analysis - Eltrombopag
The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)
- Trial name
- NCT01235988
- Testing
- Eltrombopag
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Fetal and Neonatal Alloimmune Thrombocytopenia
Towards Routine HPA-screening In Pregnancy to Prevent FNAIT
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is the most common cause of severe thrombocytopenia in otherwise healthy born neonates.
- Trial name
- HIP (NCT04067375)
- Testing
- Clinical data collection.
- Where
- Netherlands
- Volunteers
- 3,660 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT05855083
- Testing
- Biological: narsoplimab
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Omeros Corporation
Autoimmune Disease, Autoimmune Hemolytic Anemia
Treatment of Autoimmune Thrombocytopenia (AITP)
Platelets are particles found along with red and white blood cells in the blood that play a role in the process of blood clotting.
- Conditions
- Autoimmune Disease, Autoimmune Hemolytic Anemia, Thrombocytopenia
- Trial name
- NCT00001630
- Testing
- Isolex 300i
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelodysplastic Syndromes, Thrombocytopenia
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
This is a dose and schedule finding study of AMG 531 designed to assess the activity of AMG 531 to reduce the rate of clinically significant bleeding and blood transfusions in subjects with myelodysplastic syndrome (MDS)…
- Trial name
- NCT00418665
- Testing
- AMG 531
- Volunteers
- 39 people
- Sponsor
- Amgen
Anemia, Chronic Lymphocytic Leukemia
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with alvocidib in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT00735930
- Testing
- Alvocidib Hydrochloride, Lenalidomide, Pharmacological Study
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Thrombocytopenia
Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
Treating severe thrombocytopenia is a challenge in the management of systemic lupus erythematosus. Although rheumatologists have followed some rules in real practice,there is very few evidence to support the current treatment…
- Trial name
- CHORUS (NCT02444728)
- Testing
- Hydroxychloroquine, Cyclophosphamide, Azathioprine
- Where
- 15 sites in China
- Volunteers
- 50 people
- Sponsor
- Chinese SLE Treatment And Research Group
Leukemia, Lymphoma
Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets
Objectives: Determine the corrected count increment of autologous transfused platelets that had been stored by cryopreservation with ThromboSol.
- Trial name
- NCT00074763
- Testing
- Platelet Transfusion
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Primary Immune Thrombocytopenia (ITP)
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous…
- Trial name
- NCT06929299
- Testing
- STSA-1301 subcutaneous injection
- Where
- 7 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu BioJeTay Biotechnology Co., Ltd.
Myeloproliferative Neoplasms (MPNs)
WELL-MPN: A Digital Lifestyle App for Patients With MPNs
The goal of this clinical trial is to learn whether a digital lifestyle app can help improve diet, physical activity, symptoms, emotional well-being, and quality of life in adults with myeloproliferative neoplasms (MPNs).
- Trial name
- WELL-MPN (NCT07349134)
- Testing
- WELL-MPN Digital App
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Brigham and Women's Hospital
Von Willebrand Diseases
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months.
- Trial name
- NCT04053699
- Testing
- Von Willebrand Factor-Containing Product
- Where
- 15 sites in United States, Belarus and 6 more
- Volunteers
- 56 people
- Sponsor
- Octapharma